Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential - Summary - MDSpire

Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential

  • By

  • Michael Colwill

  • Sebastian Povlsen

  • Richard Pollok

  • Kamal Patel

  • James Goodhand

  • Tariq Ahmad

  • Sailish Honap

  • September 16, 2025

  • 0 min

Share

Objective:

Emphasize the significance of GLP-1RAs in IBD.

Key Findings:
  • Include specific data or examples from studies.
Interpretation:

Highlight implications for clinical practice.

Limitations:
  • Provide context on the impact of limitations on research.
Conclusion:

Reiterate the urgency for research based on findings.

Original Source(s)

Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential

  • by Michael Colwill, Sebastian Povlsen, Richard Pollok, Kamal Patel, James Goodhand, Tariq Ahmad, Sailish Honap

  • September 16, 2025

Related Content

Incidence of Clostridium difficile infection and enteric pathogens in children with inflammatory bowel disease presenting with disease exacerbation

The Impact of Metabolic Bariatric Surgery on Inflammatory Bowel Disease Risk and Outcomes in Adults With Obesity: a Propensity-matched, Nationwide, Analysis

The immunometabolic mechanisms and therapeutic targets of metabolic dysfunction-associated steatohepatitis